Totus Medicines
Updated: January 05, 2026
Founders: Neil Dhawan, Jason Pontin, Jimmy Blair
Country: USA | Funding: $106M (+)
Founded: 2020
Website: https://www.totusmedicines.com/
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
Founded: 2020
Website: https://www.totusmedicines.com/
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
